CA130 Antigen in Ovarian Cancer
Author Information
Author(s): H. Kobayashi, H. Ohi, T. Fujii, T. Terao
Primary Institution: Hamamatsu University School of Medicine
Hypothesis
Can CA130 serve as a reliable tumor marker for ovarian cancer compared to CA125?
Conclusion
CA130 is a promising tumor marker for ovarian cancer, showing high sensitivity and correlation with disease progression.
Supporting Evidence
- 91.3% of ovarian cancer patients had elevated CA130 levels.
- CA130 levels correlated with disease progression in over 95% of cases.
- CA130 showed a sensitivity of 91.3% and specificity of 75.1%.
Takeaway
CA130 is a new marker that helps doctors check if ovarian cancer is getting better or worse, just like another marker called CA125.
Methodology
The study involved serum samples from patients with ovarian cancer and benign conditions, measuring CA130 and CA125 levels using immunoradiometric assays.
Limitations
The study may have a high false-positive rate in benign conditions like endometriosis.
Participant Demographics
Patients with epithelial ovarian cancer aged 34 to 73 years, with a mean age of 58 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website